A pilot study of golexanolone, a new GABA-A receptor-modulating steroid antagonist, in patients with covert hepatic encephalopathy

Overview of attention for article published in Journal of Hepatology, April 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 10 news outlets
twitter: 25 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 79 Mendeley

So far, Altmetric has seen 12 news stories from 10 outlets.

Bausch Health’s new formulation of Xifaxan fails pair of Phase III trials

MSN, 26 Jan 2026

A new formulation of Bausch Health’s Xifaxan (rifaximin) has failed to demonstrate efficacy in two Phase III studies in hepatic…

Bausch Health’s new formulation of Xifaxan fails pair of Phase III trials

Yahoo! Finance USA, 26 Jan 2026

A new formulation of Bausch Health’s Xifaxan (rifaximin) has failed to demonstrate efficacy in two Phase III studies in hepatic…

Karolinska Development's portfolio company Umecrine Cognition publishes clinical research results in a highly regarded journal

Biz Wire Express, 22 Apr 2021

STOCKHOLM, SWEDEN 22 April 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company…

Karolinska Development's portfolio company Umecrine Cognition publishes clinical research results in a highly regarded journal

Crwe World, 22 Apr 2021

STOCKHOLM, SWEDEN 22 April 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 8 additional news stories.